English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 16 January 2024, 13:00 HKT/SGT

Source: Prota Therapeutics
Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments
Financing advances development of Prota's peanut allergy remission therapy in preparation for a Phase 3 clinical trial

MELBOURNE, Jan 16, 2024 - (ACN Newswire) - Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, today announced financing of US$21 million in equity and debt financing. The round, led by Singapore-based SPRIM Global Investments (SGI), will help the company prepare for a Phase 3 clinical investigation of the company's PRT120 oral therapy for peanut allergy.

"SPRIM brings valuable expertise, capabilities and an international investment network to Prota's technology and clinical program," said Prota Executive Chairman Kelly Constable. "This partnership and funding will accelerate Prota's drug development plans and clinical trial program, and we look forward to this strategic collaboration as Prota moves toward its Phase 3 trial."

"Closing financing in the current market validates the potential of Professor Mimi Tang's technology to deliver meaningful outcomes for patients with peanut allergy, where there is a persistent unmet need," said Dr. Paul Kelly, founding partner and director, OneVentures, one of Australia's leading Venture Capital firms with more than AU$800 million under management. "Prota's treatment offers the promise of an induction of remission of allergy, allowing patients to eat peanuts freely and enjoy an improved quality of life."

The new investment will advance the chemistry, manufacturing, and controls (CMC), accelerate the path to an Investigational New Drug Application (IND), and expand Prota's executive management team to bring on board critical expertise in late-stage drug development and commercialization.

The peanut allergy therapeutics market is projected to reach US$1 billion by 2030, growing at a compound annual rate of 10%, in part due to the increasing incidence of peanut allergy globally. In the US, peanut allergy is the most prevalent food allergy in children, affecting 2.5% of children. The most significant impact of food allergy on both patients and their families is a reduced quality-of-life and psychological distress, caused by the lifestyle and dietary restrictions of allergen avoidance and the unpredictability of reactions to accidental exposures.

Prota's technology is based on over 15 years of research led by Professor Mimi Tang at the Murdoch Children's Research Institute (MCRI).

"Our Phase 2b[1] multicenter randomized controlled trial conducted by MCRI showed that PRT120 is highly effective at inducing remission of allergy, and more importantly, leads to significant and clinically meaningful improvement in quality of life, compared with standard care (placebo treatment)," said Prota founder Professor Tang. "Long-term follow-up data further shows that children in remission have fewer reactions, less rescue epinephrine use, and far greater improvement in quality of life than children who are only desensitized, validating remission as the patient-preferred outcome."

"The food immunotherapy market is expanding rapidly with a range of therapies currently in early- through late-stage development. We are excited to support Prota in its journey to deliver a solution that can potentially transform the treatment of peanut allergy by releasing patients from the shackles of life-long maintenance dosing and allergen avoidance," said Michael Shleifer, managing partner and co-founder of SGI, a leading health sciences venture capital firm with deep industry expertise and decades of operating experience across 17 countries.

About SPRIM Global Investments (SGI)

SPRIM Global Investments (SGI) is a leading health sciences venture capital firm with deep industry expertise and decades of operating experience across 17 countries. SGI invests in biotechnology, digital health and R&D service companies to commercialize the newest technologies and accelerate innovations that are the future of health around the world. For more information, visit: www.sprim.net.

About Prota Therapeutics

Prota Therapeutics is an Australian proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel oral immunotherapy treatments for food allergy. Prota holds intellectual property covering the proprietary food immunotherapy technology developed at the MCRI. The company is, in part, a OneVentures' Healthcare Fund III investment. This fund was established with investment in part from the Australian Commonwealth Government through the BioMedical Translation Fund initiative. Prota Therapeutics has its headquarters in Melbourne, Australia. For more information please visit: https://protatherapeutics.com/.

Media Contact:
Edna Kaplan
KOGS Communication
+1 617-974-8659

---[1] Loke, PaxtonO'Sullivan, Molly et al. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. The Lancet Child & Adolescent Health, Volume 6, Issue 3, 171 - 184, 2022

Topic: Press release summary
Source: Prota Therapeutics

Sectors: BioTech
From the Asia Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Latest Press Releases
Scotts Miracle-Gro (SMG) Investor Alert: Kaplan Fox Reminds SMG Investors of a Class Action Lawsuit and August 5, 2024 Lead Plaintiff Deadline  
July 18, 2024 08:48 HKT/SGT
Hong Kong Book Fair, Sports and Leisure Expo and World of Snacks open today  
July 17, 2024 22:24 HKT/SGT
Dubai AI & Web3 Festival & Trescon Launch FutureTech World Cup to Support Global Start-ups  
July 17, 2024 21:02 HKT/SGT
ALIT Indonesia empowers marginalized children to improve their standard of living  
July 17, 2024 16:00 HKT/SGT
New Horizons for SMEs in the Johor-Singapore SEZ  
July 17, 2024 12:00 HKT/SGT
Save A Train Presents Another New and Unique Addition to its Expanding Global Rail Platform: Rail Forward!  
July 17, 2024 10:00 HKT/SGT
The Laughing Cow Brings Innovation to Snacking with Delicious Cheez Dippers  
July 17, 2024 10:00 HKT/SGT
Fujitsu-sponsored professional golfer Ayaka Furue victorious in the Amundi Evian Championship  
Tuesday, July 16, 2024 10:26:00 PM
Best BLUETTI Prime Day Deals on Portable Power Stations and Solar Generators  
July 16, 2024 22:00 HKT/SGT
'Alamein Festival' Launches Exciting Second Edition for 2024  
July 16, 2024 21:00 HKT/SGT
More Press release >>
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575